Compositions and methods of treating cancer using lipid agonists and receptors thereof
AssigneeForsyth Dental Infirmary for Children
InventorsAlpdogan Kantarci, Shevali Kansal, Hatice Hasturk, Thomas E. Van Dyke
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for preventing or treating cancer in a subject comprising overexpressing at least one Receptor for a lipid agonist, such as G-protein receptors for Resolvin. Such methods may be combined with administering Resolvins, or lipoxins and their analogs, of said Receptors to enhance the pro-resolution effects of the Resolvins, or lipoxins and their analogs, in the local, inflammatory environment where cancer cells are already present.
Claims28
A method for treating oral cancer in a subject, wherein the subject comprises cells that overexpress a G-protein coupled receptor (GPCR), wherein the GPCR is selected from the group consisting of receptor for Resolvin E1 (ERV1), G protein-coupled receptor 32 (GPR32), proResolvin mediator annexin A1 (ALX/FPR2), LO-derived eicosanoid receptors LXA4 receptor (ALX), and Leukotriene B4 receptor (BLT), the method comprising:
- administering at least one lipid agonist to the subject, wherein the at least one lipid agonist is selected from the group consisting of di-hydroxy members of the Resolvin E series, di-hydroxy members of the Resolvin D series, tri-hydroxy members of the Resolvin E series, tri-hydroxy members of the Resolvin D series, Resolvins derived from eicosapentaenoic acid (EPA), resolvins derived fromdocosahexaenoic acid (DHA), or endogenous lipoxins derived from arachidonic acid, lipoxins, and maresins.
-3. (canceled)
-12. (canceled)
(canceled)
-30. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.